sentence1 stringlengths 1.08k 96.5k | sentence2 stringlengths 51 966 | labels stringclasses 3
values | metadata stringlengths 123 2.56k |
|---|---|---|---|
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.2 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: Incidence of minor hypoglycaemia | 1 | {"evidence_spans": [{"end": 26184, "start": 25524, "text": "oglycaemia occurred in < 10% of subjects for any treatment. The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (... |
TITLE: Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial
ABSTRACT.BACKGROUND:
Endometriosis is associated with an inflammatory response. Hence infliximab, an anti-TNF-α monoclonal antibody, might relieve pain.
ABSTRACT.METHODS:
A randomized placebo-controlled t... | Intervention: Infliximab
Comparator: Placebo
Outcome: Dysmenorrhea scores | 0 | {"evidence_spans": [{"end": 1105, "start": 987, "text": "ESULTS:\r\nPain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P "}], "id": "191", "pmcid": "2517154", "prompt_id": "191", "split_group_id": "2517154", "votes": {"0": 1}} |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% | 1 | {"evidence_spans": [{"end": 16353, "start": 16120, "text": "d with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001"}, {"end": 16355, "start":... |
TITLE: Routine resite of peripheral intravenous devices every 3 days did not reduce complications compared with clinically indicated resite: a randomised controlled trial
ABSTRACT.BACKGROUND:
Peripheral intravenous device (IVD) complications were traditionally thought to be reduced by limiting dwell time. Current... | Intervention: staff inclination replacement
Comparator: routine replacement
Outcome: IVD dwell times | 1 | {"evidence_spans": [{"end": 24633, "start": 24391, "text": "of 113 hours (quartiles 72 and 172 hours) (P = 0.21). For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell tim"}, {"end": 24799,... |
TITLE: Pilot study of Lokomat versus manual-assisted treadmill training for locomotor recovery post-stroke
ABSTRACT.BACKGROUND:
While manually-assisted body-weight supported treadmill training (BWSTT) has revealed improved locomotor function in persons with post-stroke hemiparesis, outcomes are inconsistent and i... | Intervention: Body-weight supported treadmill training combined with Lokomat (Post-test)
Comparator: Body-weight supported treadmill training combined with Lokomat (Pre-test)
Outcome: Berg Balance Scale score | 1 | {"evidence_spans": [{"end": 24120, "start": 23992, "text": "ovements in 5 of 8 participants. Berg Balance Scale scores significantly improved in both the Lokomat group, p = 0.04, effect si"}], "id": "163", "pmcid": "2708184", "prompt_id": "163", "split_group_id": "2708184", "votes": {"1": 1}} |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (all doses) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: HOMA-IR | 0 | {"evidence_spans": [{"end": 21012, "start": 20943, "text": "mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051). There were no s"}], "id": "140", "pmcid": "2871176", "prompt_id": "140", "split_group_id": "2871176", "votes": {"0": 4}} |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (0.6 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: HbA1c level at 26 weeks | -1 | {"evidence_spans": [{"end": 14314, "start": 13955, "text": "or rosiglitazone (\u22120.4%) (Fig. 3d). Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: \u22121.4% (1.6, \u22121.1); liraglutide 1.2 mg: \u22121.3% (1.5, \u22121.1); liraglutide 0.6 mg: \u22120.8% (\u22121.1, \u22120.6); rosig... |
TITLE: Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial
ABSTRACT.BACKGROUND:
Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its ... | Intervention: Dihydroartemisinin-piperaquine
Comparator: Chloroquine
Outcome: Parasite clearance at day 2 | 0 | {"evidence_spans": [{"end": 22940, "start": 22725, "text": "k of clearance in chloroquine group = 0.87, 95% CI 0.81-0.93). At day 2, the groups were no longer significantly different with 259/265 (97.8%) of the dihydroartemisinin-piperaquine group and 257/265 (97.0%) in the "}], "id": "169", "pmcid": "2864284", "prompt... |
TITLE: Pilot study of Lokomat versus manual-assisted treadmill training for locomotor recovery post-stroke
ABSTRACT.BACKGROUND:
While manually-assisted body-weight supported treadmill training (BWSTT) has revealed improved locomotor function in persons with post-stroke hemiparesis, outcomes are inconsistent and i... | Intervention: Body-weight supported treadmill training combined with Lokomat (Post-test)
Comparator: Body-weight supported treadmill training combined with Lokomat (Pre-test)
Outcome: Physical performance battery scores | 1 | {"evidence_spans": [{"end": 23991, "start": 23824, "text": " group participants (Figure 2B). Similarly, short physical performance battery scores were improved in the Lokomat group, p = 0.04, with an effect size of 0.29 and imp"}], "id": "162", "pmcid": "2708184", "prompt_id": "162", "split_group_id": "2708184", "votes... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: Reductions in systolic blood pressure | 0 | {"evidence_spans": [{"end": 22230, "start": 22039, "text": "ied forward. \r\n\r\nBODY.RESULTS.BLOOD PRESSURE AND PULSE:\r\nAlthough decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6\u20132.8 mmHg), they were not significant"}, {"end": 22232, "start": 22039, "text": "ied forward. \... |
TITLE: Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial
ABSTRACT.BACKGROUND:
Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its ... | Intervention: Dihydroartemisinin-piperaquine
Comparator: Chloroquine
Outcome: Parasitaemias associated with gametocytaemia | 0 | {"evidence_spans": [{"end": 24182, "start": 23890, "text": " group and day 42 in the dihydroartemisinin-piperaquine group. Twenty-one of 30 (70%) recurrent parasitaemias were associated with gametocytaemia, with no significant difference between treatment arms in terms of proportion of recurrent patients with gametocyt... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: Pulse variations | 1 | {"evidence_spans": [{"end": 22640, "start": 22373, "text": "Hg), with no significant differences between treatments. Pulse increases above baseline ranged from 2 to 4 beats/min with the three doses of liraglutide and 1 beat/min with rosiglitazone, while pulse decreased by 1 beat/min with placebo. Changes in pulse for a... |
TITLE: Is the operative delivery rate in low-risk women dependent on the level of birth care? A randomised controlled trial
ABSTRACT.OBJECTIVE:
To investigate possible differences in operative delivery rate among low-risk women, randomised to an alongside midwifery-led unit or to standard obstetric units within t... | Intervention: Midwife-led unit
Comparator: Normal unit & Special unit
Outcome: Pain relief: Epidural anesthesia | -1 | {"evidence_spans": [{"end": 22271, "start": 22080, "text": "ly.\r\n\r\nBODY.RESULTS.MODE OF DELIVERY.PAIN RELIEF:\r\nOf all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11\u20131.9"}, {"end": 22272, "start": 22080, "text": "ly.\r\n\r\nBOD... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.2 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: Pulse variations | 1 | {"evidence_spans": [{"end": 22738, "start": 22373, "text": "Hg), with no significant differences between treatments. Pulse increases above baseline ranged from 2 to 4 beats/min with the three doses of liraglutide and 1 beat/min with rosiglitazone, while pulse decreased by 1 beat/min with placebo. Changes in pulse for a... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.2 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: Incidence of minor hypoglycaemia | 1 | {"evidence_spans": [{"end": 26184, "start": 25524, "text": "oglycaemia occurred in < 10% of subjects for any treatment. The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (... |
TITLE: Routine resite of peripheral intravenous devices every 3 days did not reduce complications compared with clinically indicated resite: a randomised controlled trial
ABSTRACT.BACKGROUND:
Peripheral intravenous device (IVD) complications were traditionally thought to be reduced by limiting dwell time. Current... | Intervention: routine replacement
Comparator: staff inclination replacement
Outcome: phlebitis | 0 | {"evidence_spans": [{"end": 1634, "start": 1549, "text": "= 0.53). There were no local infections or IVD-related bloodstream infections in eith"}, {"end": 21796, "start": 21762, "text": "83.1) HR 1.03 (0.74, 1.43), p = 0."}, {"end": 24020, "start": 23843, "text": "ESULTS.EFFECT OF INTERVENTION ON SECONDARY OUTCOMES:\r\... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (all doses) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: Changes in calcitonin at week 26 | 0 | {"evidence_spans": [{"end": 26703, "start": 26515, "text": ", biochemistry, urinalysis, haematology or ECG assessments. No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either "}], "id": "154", "pmcid": "2871176", "prompt_id": "154", "split_group_i... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: Postprandial plasma glucose | -1 | {"evidence_spans": [{"end": 1756, "start": 1469, "text": "mmol/l). Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [\u22122.5 to \u22122.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (\u22120.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazon... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.2 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l | 1 | {"evidence_spans": [{"end": 18476, "start": 18230, "text": " \u2020\u2020P < 0.01 compared with rosiglitazone. The percentage of subjects achieving FPG values between 5.0 mmol/l and \u2264 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (... |
TITLE: Immunogenicity and Smoking Cessation Outcomes for a Novel Nicotine Immunotherapeutic
ABSTRACT:
NicVAX®, a nicotine vaccine (3'AmNic-rEPA), has been clinically evaluated to determine if higher antibody concentrations are associated with higher smoking abstinence rates and if doses and frequency of administr... | Intervention: recipients with the highest serum anti-nicotine antibody response (top 30% by AUC)
Comparator: placebo group
Outcome: attain 8 weeks continuous abstinence from weeks 19 through 26 | 1 | {"evidence_spans": [{"end": 831, "start": 556, "text": "o. 3'AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% C... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (0.6 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: Postprandial plasma glucose | -1 | {"evidence_spans": [{"end": 19251, "start": 19128, "text": "raglutide 0.6 mg and 0.4 mmol/l for placebo. Treatment differences for PPG were greater with all doses of liraglutide compa"}, {"end": 19252, "start": 19128, "text": "raglutide 0.6 mg and 0.4 mmol/l for placebo. Treatment differences for PPG were greater with ... |
TITLE: Pilot study of Lokomat versus manual-assisted treadmill training for locomotor recovery post-stroke
ABSTRACT.BACKGROUND:
While manually-assisted body-weight supported treadmill training (BWSTT) has revealed improved locomotor function in persons with post-stroke hemiparesis, outcomes are inconsistent and i... | Intervention: Fast treadmill speed
Comparator: Slow treadmill speed
Outcome: Locomotor-training effects | 0 | {"evidence_spans": [{"end": 26776, "start": 26502, "text": "d using the 6-minute walk test. Our second aim was to assess locomotor-training effects at faster vs. slower treadmill speeds. As anticipated, independent of whether training occurred in the Lokomat or manual-BWSTT mode, average weekly training speeds within ... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: HbA1c level at 26 weeks | -1 | {"evidence_spans": [{"end": 1081, "start": 843, "text": "ESULTS:\r\nLiraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (\u22121.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (\u22120.4%, P < 0.0001, baseline 8.4%) when added to gli"}, {"end": 1... |
TITLE: Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial
ABSTRACT.BACKGROUND:
Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its ... | Intervention: Dihydroartemisinin-piperaquine
Comparator: Chloroquine
Outcome: Recurrent infections at day 56 | -1 | {"evidence_spans": [{"end": 1663, "start": 1417, "text": "roquine. At day 56, there were more recurrent infections in the chloroquine arm (8.9%, 95% CI 6.0-13.1%) than the dihydroartemisinin-piperaquine arm (2.8%, 95% CI 1.4-5.8%), a difference in cumulative recurrence rate of 6.1% (2-sided 90%CI +2.6 t"}, {"end": 2065... |
TITLE: Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial
ABSTRACT.BACKGROUND:
Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its ... | Intervention: Dihydroartemisinin-piperaquine
Comparator: Chloroquine
Outcome: Baseline white blood cell count | 1 | {"evidence_spans": [{"end": 18057, "start": 17779, "text": "r methods.\r\n\r\nBODY.RESULTS.BASELINE CHARACTERISTICS:\r\nPatient characteristics at baseline were broadly similar between the two treatment groups (Table 1) except that the median white blood cell count was lower in the chloroquine group compared with dihyd... |
TITLE: Pilot study of Lokomat versus manual-assisted treadmill training for locomotor recovery post-stroke
ABSTRACT.BACKGROUND:
While manually-assisted body-weight supported treadmill training (BWSTT) has revealed improved locomotor function in persons with post-stroke hemiparesis, outcomes are inconsistent and i... | Intervention: Body-weight supported treadmill training combined with Lokomat
Comparator: Manually-assisted body-weight supported treadmill training
Outcome: Paretic step length ratio | 0 | {"evidence_spans": [{"end": 1330, "start": 1211, "text": "ESULTS:\r\nNo significant differences in primary outcomes were revealed between Lokomat and manual groups as a result of "}], "id": "156", "pmcid": "2708184", "prompt_id": "156", "split_group_id": "2708184", "votes": {"0": 1}} |
TITLE: Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial
ABSTRACT.BACKGROUND:
Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its ... | Intervention: Dihydroartemisinin-piperaquine
Comparator: Chloroquine
Outcome: Superiority of treatment given by survival curves | 1 | {"evidence_spans": [{"end": 1801, "start": 1664, "text": " +9.7%). The log-rank test comparing the survival curves confirmed the superiority of dihydroartemisinin-piperaquine over chloroquine (p "}], "id": "171", "pmcid": "2864284", "prompt_id": "171", "split_group_id": "2864284", "votes": {"1": 1}} |
TITLE: Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial
ABSTRACT.BACKGROUND:
Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its ... | Intervention: Dihydroartemisinin-piperaquine
Comparator: Chloroquine
Outcome: Headache | -1 | {"evidence_spans": [{"end": 23717, "start": 23560, "text": "emisinin-piperaquine, 9/264 (3.4%) for chloroquine, p = 0.08). At day 1, headache was less frequent in the dihydroartemisinin-piperaquine arm (105/265 (39.6%"}], "id": "176", "pmcid": "2864284", "prompt_id": "176", "split_group_id": "2864284", "votes": {"-1": ... |
TITLE: Routine resite of peripheral intravenous devices every 3 days did not reduce complications compared with clinically indicated resite: a randomised controlled trial
ABSTRACT.BACKGROUND:
Peripheral intravenous device (IVD) complications were traditionally thought to be reduced by limiting dwell time. Current... | Intervention: routine replacement
Comparator: staff inclination replacement
Outcome: IVD complications per person | 0 | {"evidence_spans": [{"end": 2144, "start": 1923, "text": "NCLUSIONS:\r\nResite on clinical indication would allow one in two patients to have a single cannula per course of IV treatment, as opposed to one in five patients managed with routine resite; overall complication rates app"}, {"end": 21357, "start": 21144, "tex... |
TITLE: Routine resite of peripheral intravenous devices every 3 days did not reduce complications compared with clinically indicated resite: a randomised controlled trial
ABSTRACT.BACKGROUND:
Peripheral intravenous device (IVD) complications were traditionally thought to be reduced by limiting dwell time. Current... | Intervention: routine replacement
Comparator: staff inclination replacement
Outcome: cost per patient | 1 | {"evidence_spans": [{"end": 1899, "start": 1635, "text": "r group. IV therapy duration did not differ between groups (P = 0.22), but more (P = 0.004) IVDs were placed per patient in the routine replacement (mean, 1.8) than the clinical indication group (mean, 1.5), with significantly higher hospital costs per patient (... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: HbA1c level at 26 weeks | -1 | {"evidence_spans": [{"end": 1081, "start": 843, "text": "ESULTS:\r\nLiraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (\u22121.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (\u22120.4%, P < 0.0001, baseline 8.4%) when added to gli"}, {"end": 1... |
TITLE: Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial
ABSTRACT.BACKGROUND:
Endometriosis is associated with an inflammatory response. Hence infliximab, an anti-TNF-α monoclonal antibody, might relieve pain.
ABSTRACT.METHODS:
A randomized placebo-controlled t... | Intervention: Infliximab
Comparator: Placebo
Outcome: Bleeding during surgery | 0 | {"evidence_spans": [{"end": 20944, "start": 20742, "text": ") and 8.2 (3\u201315) mm, respectively. During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the durati"}, {"end": 20945, "start": 20742, "text": ") and 8.2... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: Proinsulin : insulin ratio | -1 | {"evidence_spans": [{"end": 20726, "start": 20566, "text": "F PANCREATIC B-CELL FUNCTION AND INSULIN RESISTANCE:\r\nReductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared wi"}, {"end": 20728, "start": 20566, "text": "F PANCREATIC B-CELL FUNCTION AND INSULIN RESISTANCE:\r... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.2 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: Postprandial plasma glucose | -1 | {"evidence_spans": [{"end": 1691, "start": 1469, "text": "mmol/l). Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [\u22122.5 to \u22122.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (\u22120.4 mmol/l, P < 0.0001, baseline 12."}, {"end": 1692, "start"... |
TITLE: Pilot study of Lokomat versus manual-assisted treadmill training for locomotor recovery post-stroke
ABSTRACT.BACKGROUND:
While manually-assisted body-weight supported treadmill training (BWSTT) has revealed improved locomotor function in persons with post-stroke hemiparesis, outcomes are inconsistent and i... | Intervention: Body-weight supported treadmill training combined with Lokomat (Post-test)
Comparator: Body-weight supported treadmill training combined with Lokomat (Pre-test)
Outcome: Self-selected overground walk velocity | 1 | {"evidence_spans": [{"end": 22490, "start": 22194, "text": "ion and disability instrument. Although an equal number of participants (n = 7) produced a training related increase in self-selected overground walking speed in each group, a significant difference, p = 0.04, was revealed only in the Lokomat group with a pr... |
TITLE: Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial
ABSTRACT.BACKGROUND:
Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its ... | Intervention: Dihydroartemisinin-piperaquine
Comparator: Chloroquine
Outcome: Fever resolution by day 1 | 1 | {"evidence_spans": [{"end": 23385, "start": 23104, "text": "ce of parasites (a) and fever (b) at day 1-3 after treatment. In terms of resolution of fever (defined as axillary temperature >37.0\u00b0C) dihydroartemisinin-piperaquine was again superior (Figure 4), with 29/266 (10.9%) of the dihydroartemisinin-piperaquin... |
TITLE: Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial
ABSTRACT.BACKGROUND:
Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its ... | Intervention: Dihydroartemisinin-piperaquine
Comparator: Chloroquine
Outcome: Pruritus | -1 | {"evidence_spans": [{"end": 24755, "start": 24365, "text": " hospitalization. Both study drugs appeared to be well tolerated. There was a significant increase in the proportion of patients with pruritus in the chloroquine arm compared to dihydroartemisinin-piperaquine on days 1, 2 and 3; on day 1, 15/268 subjects in th... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (0.6 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: ADA postprandial plasma glucose goals less than 10.0 mmol/l | 1 | {"evidence_spans": [{"end": 19601, "start": 19433, "text": "SULTS.EFFICACY.PPG MEASUREMENTS < 10.0 MMOL/L:\r\nThe percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses"}, {"end": 19623, "start": 19433, "text": "SULTS.EFFICACY.PPG MEASUREMENTS < 10.0 MMOL/L:... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (0.6 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l | 1 | {"evidence_spans": [{"end": 18474, "start": 18230, "text": " \u2020\u2020P < 0.01 compared with rosiglitazone. The percentage of subjects achieving FPG values between 5.0 mmol/l and \u2264 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg "... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.2 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: Proinsulin : insulin ratio | -1 | {"evidence_spans": [{"end": 20726, "start": 20566, "text": "F PANCREATIC B-CELL FUNCTION AND INSULIN RESISTANCE:\r\nReductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared wi"}, {"end": 20728, "start": 20566, "text": "F PANCREATIC B-CELL FUNCTION AND INSULIN RESISTANCE:\r... |
TITLE: Is the operative delivery rate in low-risk women dependent on the level of birth care? A randomised controlled trial
ABSTRACT.OBJECTIVE:
To investigate possible differences in operative delivery rate among low-risk women, randomised to an alongside midwifery-led unit or to standard obstetric units within t... | Intervention: Midwife-led unit
Comparator: Normal unit & Special unit
Outcome: Labour dystocia | -1 | {"evidence_spans": [{"end": 21464, "start": 21274, "text": "0 minutes for multiparous women without epidural. In the MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65\u20130.96) "}, {"end": 21475, "start": 21276, "text": "minutes for multiparo... |
TITLE: Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial
ABSTRACT.BACKGROUND:
Endometriosis is associated with an inflammatory response. Hence infliximab, an anti-TNF-α monoclonal antibody, might relieve pain.
ABSTRACT.METHODS:
A randomized placebo-controlled t... | Intervention: Infliximab
Comparator: Placebo
Outcome: Pain killers intake | 1 | {"evidence_spans": [{"end": 23041, "start": 22930, "text": "mates are not entirely independent. Over the whole observation period, the infliximab group had a slightly high"}, {"end": 23157, "start": 22930, "text": "mates are not entirely independent. Over the whole observation period, the infliximab group had a slightl... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l | 1 | {"evidence_spans": [{"end": 18476, "start": 18230, "text": " \u2020\u2020P < 0.01 compared with rosiglitazone. The percentage of subjects achieving FPG values between 5.0 mmol/l and \u2264 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (... |
TITLE: Is the operative delivery rate in low-risk women dependent on the level of birth care? A randomised controlled trial
ABSTRACT.OBJECTIVE:
To investigate possible differences in operative delivery rate among low-risk women, randomised to an alongside midwifery-led unit or to standard obstetric units within t... | Intervention: Midwife-led unit
Comparator: Normal unit & Special unit
Outcome: Postpartum haemorrhage | 0 | {"evidence_spans": [{"end": 1272, "start": 983, "text": "\r\nABSTRACT.RESULTS:\r\nThere were no significant differences in total operative deliveries between the three units: 16.3% in the midwife-led unit; 18.0% in the normal unit; and 18.8% in the special unit. There were no significant differences in postpartum haemo... |
TITLE: Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial
ABSTRACT.BACKGROUND:
Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its ... | Intervention: Dihydroartemisinin-piperaquine
Comparator: Chloroquine
Outcome: Serious adverse events | 0 | {"evidence_spans": [{"end": 2007, "start": 1929, "text": "urrence. Both regimens were well tolerated and no serious adverse events were "}], "id": "172", "pmcid": "2864284", "prompt_id": "172", "split_group_id": "2864284", "votes": {"0": 1}} |
TITLE: Trends in Use of Referral Hospital Services for Care of Sick Newborns in a Community-based Intervention in Tangail District, Bangladesh
ABSTRACT:
The Projahnmo-II Project in Mirzapur upazila (sub-district), Tangail district, Bangladesh, is promoting care-seeking for sick newborns through health education o... | Intervention: Promotion by CHWs of maternal and newborn-care interventions
Comparator: Comparison arm
Outcome: Care-seeking from unqualified providers (such as village doctors) for ill newborns | -1 | {"evidence_spans": [{"end": 26183, "start": 25911, "text": " (Fig. 3 and Row 9\u201312 of Table 2). Finally, Figure 4 demonstrates that the proportion of families who sought care from unqualified providers, such as unlicensed village doctors, remained unchanged in the comparison arm, but declined significantly in the i... |
TITLE: Immunogenicity and Smoking Cessation Outcomes for a Novel Nicotine Immunotherapeutic
ABSTRACT:
NicVAX®, a nicotine vaccine (3'AmNic-rEPA), has been clinically evaluated to determine if higher antibody concentrations are associated with higher smoking abstinence rates and if doses and frequency of administr... | Intervention: high Ab group
Comparator: placebo
Outcome: Prolonged abstinence from smoking rates to 6 months | 1 | {"evidence_spans": [{"end": 5050, "start": 4833, "text": "70% of responders. 3'AmNic-rEPA recipients in the high Ab group were significantly more likely to attain 8 weeks of continuous abstinence from weeks 19 through 26 than placebo (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% C"}, {"end": 7845, "start": 7692, "text": "eks... |
TITLE: Efficacy of positive end-expiratory pressure titration after the alveolar recruitment manoeuvre in patients with acute respiratory distress syndrome
ABSTRACT.INTRODUCTION:
In acute respiratory distress syndrome (ARDS), adequate positive end-expiratory pressure (PEEP) may decrease ventilator-induced lung in... | Intervention: Decremental PEEP titration group
Comparator: table-based PEEP (control) group
Outcome: The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents of patients with ARDS | 0 | {"evidence_spans": [{"end": 1856, "start": 1634, "text": "st week. The duration of use of paralysing or sedative agents, mechanical ventilation, stay in the intensive care unit and mortality at 28 days did not differ significantly between the decremental PEEP titration and contro"}, {"end": 18210, "start": 18075, "text... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.2 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: Reductions in systolic blood pressure | 0 | {"evidence_spans": [{"end": 22199, "start": 22039, "text": "ied forward. \r\n\r\nBODY.RESULTS.BLOOD PRESSURE AND PULSE:\r\nAlthough decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6\u20132.8 m"}, {"end": 22230, "start": 22039, "text": "ied forward. \r\n\r\nBODY.RESULTS.BLOOD PRESS... |
TITLE: Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial
ABSTRACT.BACKGROUND:
Endometriosis is associated with an inflammatory response. Hence infliximab, an anti-TNF-α monoclonal antibody, might relieve pain.
ABSTRACT.METHODS:
A randomized placebo-controlled t... | Intervention: Infliximab
Comparator: Placebo
Outcome: Severity of pain | 0 | {"evidence_spans": [{"end": 1105, "start": 987, "text": "ESULTS:\r\nPain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P "}, {"end": 1184, "start": 987, "text": "ESULTS:\r\nPain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and inf... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: Incidence of minor hypoglycaemia | 1 | {"evidence_spans": [{"end": 26184, "start": 25524, "text": "oglycaemia occurred in < 10% of subjects for any treatment. The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.2 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% | 1 | {"evidence_spans": [{"end": 16449, "start": 15735, "text": ".EFFICACY.PERCENTAGE REACHING AN HBA:\r\nThe percentage of subjects reaching ADA [2] and International Diabetes Federation (IDF)/American Association of Clinical Endocrinologists (AACE) [11,12] treatment HbA1c goals with liraglutide was dose dependent (Fig. 4)... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (all doses) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: Changes in calcitonin at week 26 | 0 | {"evidence_spans": [{"end": 26703, "start": 26515, "text": ", biochemistry, urinalysis, haematology or ECG assessments. No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either "}], "id": "153", "pmcid": "2871176", "prompt_id": "153", "split_group_i... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.2 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: Fasting plasma glucose at week 26 | -1 | {"evidence_spans": [{"end": 1468, "start": 1144, "text": "e 8.4%). Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) ... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (all doses) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: ADA postprandial plasma glucose goals less than 10.0 mmol/l | 0 | {"evidence_spans": [{"end": 19624, "start": 19433, "text": "SULTS.EFFICACY.PPG MEASUREMENTS < 10.0 MMOL/L:\r\nThe percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compare"}], "id": "129", "pmcid": "2871176", "prompt_id": "129", "split_gr... |
TITLE: Is the operative delivery rate in low-risk women dependent on the level of birth care? A randomised controlled trial
ABSTRACT.OBJECTIVE:
To investigate possible differences in operative delivery rate among low-risk women, randomised to an alongside midwifery-led unit or to standard obstetric units within t... | Intervention: Midwife-led unit
Comparator: Normal unit & Special unit
Outcome: Oxytocin infusion for augmentation of labour | -1 | {"evidence_spans": [{"end": 21699, "start": 21475, "text": "n the SU (RR 0.72, 95% CI 0.59\u20130.89) (Table 2). Of all women allocated to the MU, 26.2% were given oxytocin infusion for augmentation of labour, which was significantly lower than 36.7% in the NU (RR 0.73, 95% CI 0.59\u20130.89) "}, {"end": 21709, "start"... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.2 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: Postprandial plasma glucose | -1 | {"evidence_spans": [{"end": 1756, "start": 1469, "text": "mmol/l). Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [\u22122.5 to \u22122.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (\u22120.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazon... |
TITLE: Immunogenicity and Smoking Cessation Outcomes for a Novel Nicotine Immunotherapeutic
ABSTRACT:
NicVAX®, a nicotine vaccine (3'AmNic-rEPA), has been clinically evaluated to determine if higher antibody concentrations are associated with higher smoking abstinence rates and if doses and frequency of administr... | Intervention: non-abstainers (weeks 19–52) with high Ab levels
Comparator: non-abstainers in the placebo group
Outcome: Reduction of daily cigarette consumption and cotinine | 1 | {"evidence_spans": [{"end": 8520, "start": 8258, "text": "OKING IN NON-QUITTERS:\r\nStatistically significant differences were observed in reduction of daily cigarette consumption and cotinine between non-abstainers (weeks 19\u201352) with high Ab levels and non-abstainers in the placebo group (p=0.0015 and 0.019, resp... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (0.6 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: Fasting plasma glucose at week 26 | -1 | {"evidence_spans": [{"end": 17913, "start": 17497, "text": "RESULTS.EFFICACY.FASTING PLASMA GLUCOSE:\r\nBy week 2, subjects treated with liraglutide had rapid and larger decreases in FPG vs. comparator treatment. At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001), while only l... |
TITLE: Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial
ABSTRACT.BACKGROUND:
Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its ... | Intervention: Dihydroartemisinin-piperaquine
Comparator: Chloroquine
Outcome: Parasite clearance at day 1 | 1 | {"evidence_spans": [{"end": 22724, "start": 22383, "text": "cified survival analysis.\r\n\r\nBODY.RESULTS.SECONDARY OUTCOMES:\r\nInitial parasitological responses were faster with dihydroartemisinin-piperaquine (Figure 4); in the dihydroartemisinin-piperaquine group 241/264 (91.3%) of patients cleared their parasitaemi... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: HOMA-B | 1 | {"evidence_spans": [{"end": 20816, "start": 20728, "text": " either rosiglitazone or placebo (Table 2; P \u2264 0.02). HOMA-B increased with liraglutide "}, {"end": 20817, "start": 20728, "text": " either rosiglitazone or placebo (Table 2; P \u2264 0.02). HOMA-B increased with liraglutide ("}, {"end": 20942, "start": 2... |
TITLE: Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial
ABSTRACT.BACKGROUND:
Endometriosis is associated with an inflammatory response. Hence infliximab, an anti-TNF-α monoclonal antibody, might relieve pain.
ABSTRACT.METHODS:
A randomized placebo-controlled t... | Intervention: Infliximab
Comparator: Placebo
Outcome: Nodules diameters | 0 | {"evidence_spans": [{"end": 20236, "start": 20145, "text": "< 0.001) were analysed separately. No effect of treatment was found upon the mean diameter"}, {"end": 20494, "start": 20145, "text": "< 0.001) were analysed separately. No effect of treatment was found upon the mean diameters of the nodules as measured by TV... |
TITLE: Trends in Use of Referral Hospital Services for Care of Sick Newborns in a Community-based Intervention in Tangail District, Bangladesh
ABSTRACT:
The Projahnmo-II Project in Mirzapur upazila (sub-district), Tangail district, Bangladesh, is promoting care-seeking for sick newborns through health education o... | Intervention: Promotion by CHWs of maternal and newborn-care interventions
Comparator: Comparison arm
Outcome: Care-seeking from qualified providers for ill newborns | 1 | {"evidence_spans": [{"end": 25646, "start": 25348, "text": "n how the survey was administered. Figure 2 demonstrates that there was a highly significant (p<0.00001) increase in the proportion of families that sought care from qualified providers for sick newborns in the intervention arm (Fig. 2 and Rows 5 and 7 of Tabl... |
TITLE: Is the operative delivery rate in low-risk women dependent on the level of birth care? A randomised controlled trial
ABSTRACT.OBJECTIVE:
To investigate possible differences in operative delivery rate among low-risk women, randomised to an alongside midwifery-led unit or to standard obstetric units within t... | Intervention: Midwife-led unit
Comparator: Normal unit & Special unit
Outcome: Pain relief: Acupuncture | 1 | {"evidence_spans": [{"end": 22498, "start": 22272, "text": ") and 24.8% in the SU (RR 1.57, 95% CI 1.16\u20132.13). The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25\u20131.69) a"}], "id": "197", "pmcid... |
TITLE: Pilot study of Lokomat versus manual-assisted treadmill training for locomotor recovery post-stroke
ABSTRACT.BACKGROUND:
While manually-assisted body-weight supported treadmill training (BWSTT) has revealed improved locomotor function in persons with post-stroke hemiparesis, outcomes are inconsistent and i... | Intervention: Body-weight supported treadmill training combined with Lokomat (Post-test)
Comparator: Body-weight supported treadmill training combined with Lokomat (Pre-test)
Outcome: Improvement in lower extremity Fugl-Meyer score | 1 | {"evidence_spans": [{"end": 23810, "start": 23504, "text": "d in the manual group (Table 2). Fast overground walk speed improved from pre- to post-training in 6 of 8 Lokomat participants, p = 0.05, with a small effect size of 0.15 (Figure 2A). Lower extremity Fugl-Meyer score improvements were also noted, p = 0.04, wit... |
TITLE: Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial
ABSTRACT.BACKGROUND:
Endometriosis is associated with an inflammatory response. Hence infliximab, an anti-TNF-α monoclonal antibody, might relieve pain.
ABSTRACT.METHODS:
A randomized placebo-controlled t... | Intervention: Infliximab
Comparator: Placebo
Outcome: Extend of the disease as visualized during surgery | 0 | {"evidence_spans": [{"end": 20864, "start": 20742, "text": ") and 8.2 (3\u201315) mm, respectively. During surgery, no obvious differences were observed in the extend of the disease, the"}, {"end": 20945, "start": 20742, "text": ") and 8.2 (3\u201315) mm, respectively. During surgery, no obvious differences were obse... |
TITLE: Efficacy of positive end-expiratory pressure titration after the alveolar recruitment manoeuvre in patients with acute respiratory distress syndrome
ABSTRACT.INTRODUCTION:
In acute respiratory distress syndrome (ARDS), adequate positive end-expiratory pressure (PEEP) may decrease ventilator-induced lung in... | Intervention: Decremental PEEP titration group
Comparator: table-based PEEP (control) group
Outcome: The survival rate / overall mortality of patients with ARDS | 0 | {"evidence_spans": [{"end": 1856, "start": 1634, "text": "st week. The duration of use of paralysing or sedative agents, mechanical ventilation, stay in the intensive care unit and mortality at 28 days did not differ significantly between the decremental PEEP titration and contro"}, {"end": 16588, "start": 16242, "text... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: Postprandial plasma glucose | -1 | {"evidence_spans": [{"end": 1691, "start": 1469, "text": "mmol/l). Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [\u22122.5 to \u22122.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (\u22120.4 mmol/l, P < 0.0001, baseline 12."}, {"end": 1692, "start"... |
TITLE: Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial
ABSTRACT.BACKGROUND:
Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its ... | Intervention: Dihydroartemisinin-piperaquine
Comparator: Chloroquine
Outcome: Haemoglobin concentration | 0 | {"evidence_spans": [{"end": 25082, "start": 24901, "text": "ment were found to be significantly different between the groups. There were no significant differences between the two arms in haemoglobin concentration or occurrence of anaemia (h"}], "id": "180", "pmcid": "2864284", "prompt_id": "180", "split_group_id": "28... |
TITLE: Immunogenicity and Smoking Cessation Outcomes for a Novel Nicotine Immunotherapeutic
ABSTRACT:
NicVAX®, a nicotine vaccine (3'AmNic-rEPA), has been clinically evaluated to determine if higher antibody concentrations are associated with higher smoking abstinence rates and if doses and frequency of administr... | Intervention: low Ab group
Comparator: placebo
Outcome: Prolonged abstinence from smoking rates to 6 months | 0 | {"evidence_spans": [{"end": 7941, "start": 7692, "text": "eks, respectively). Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53\u201312.71) with no significant differences between the placebo and low Ab groups (7.9"}, {"en... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.2 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: HOMA-B | 1 | {"evidence_spans": [{"end": 20816, "start": 20728, "text": " either rosiglitazone or placebo (Table 2; P \u2264 0.02). HOMA-B increased with liraglutide "}, {"end": 20817, "start": 20728, "text": " either rosiglitazone or placebo (Table 2; P \u2264 0.02). HOMA-B increased with liraglutide ("}, {"end": 20941, "start": 2... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (all doses) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: HOMA-IR | 0 | {"evidence_spans": [{"end": 21012, "start": 20943, "text": "mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051). There were no s"}], "id": "139", "pmcid": "2871176", "prompt_id": "139", "split_group_id": "2871176", "votes": {"0": 4}} |
TITLE: Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial
ABSTRACT.BACKGROUND:
Endometriosis is associated with an inflammatory response. Hence infliximab, an anti-TNF-α monoclonal antibody, might relieve pain.
ABSTRACT.METHODS:
A randomized placebo-controlled t... | Intervention: Infliximab
Comparator: Placebo
Outcome: Endometrial thickness | 0 | {"evidence_spans": [{"end": 20742, "start": 20494, "text": "it 6, 13.2 + 3.4 and 15.1 + 2.38 mm. Endometrial thickness was not affected by treatment, being at baseline and at the end of the treatment period for the infliximab group 5.2 (range 1.3\u201318) and 7.8 (1.9\u201311) mm and for the placebo group 7.7 (1.8\u201... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.2 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: Fasting plasma glucose at week 26 | -1 | {"evidence_spans": [{"end": 1396, "start": 1144, "text": "e 8.4%). Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9."}, {"end"... |
TITLE: Routine resite of peripheral intravenous devices every 3 days did not reduce complications compared with clinically indicated resite: a randomised controlled trial
ABSTRACT.BACKGROUND:
Peripheral intravenous device (IVD) complications were traditionally thought to be reduced by limiting dwell time. Current... | Intervention: routine replacement
Comparator: staff inclination replacement
Outcome: occlusion | 0 | {"evidence_spans": [{"end": 21958, "start": 21896, "text": "3 (30%) 61 (33%) RR 1.10 (0.81, 1.49), p = 0.57 Occlusion, n ("}, {"end": 24020, "start": 23843, "text": "ESULTS.EFFECT OF INTERVENTION ON SECONDARY OUTCOMES:\r\nThere was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), ... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.2 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: HbA1c level at 26 weeks | -1 | {"evidence_spans": [{"end": 1002, "start": 843, "text": "ESULTS:\r\nLiraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (\u22121.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, basel"}, {"end": 1003, "start": 843, "text": "ESULTS:\r\nLiraglutide (1.2 or 1.8 mg) produced greater ... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: Reductions in systolic blood pressure | 0 | {"evidence_spans": [{"end": 22231, "start": 22039, "text": "ied forward. \r\n\r\nBODY.RESULTS.BLOOD PRESSURE AND PULSE:\r\nAlthough decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6\u20132.8 mmHg), they were not significantl"}, {"end": 22232, "start": 22039, "text": "ied forward. ... |
TITLE: Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial
ABSTRACT.BACKGROUND:
Endometriosis is associated with an inflammatory response. Hence infliximab, an anti-TNF-α monoclonal antibody, might relieve pain.
ABSTRACT.METHODS:
A randomized placebo-controlled t... | Intervention: Infliximab
Comparator: Placebo
Outcome: Pain estimates after surgery | 0 | {"evidence_spans": [{"end": 1275, "start": 1185, "text": "easures. After surgery, pain scores decreased in both groups to less than 20% of the initi"}, {"end": 21243, "start": 21029, "text": "ifferences between the two groups. After surgery, all pain estimates decreased to less than 10% of the baseline in both groups ... |
TITLE: Pilot study of Lokomat versus manual-assisted treadmill training for locomotor recovery post-stroke
ABSTRACT.BACKGROUND:
While manually-assisted body-weight supported treadmill training (BWSTT) has revealed improved locomotor function in persons with post-stroke hemiparesis, outcomes are inconsistent and i... | Intervention: Body-weight supported treadmill training combined with Lokomat (Post-test)
Comparator: Body-weight supported treadmill training combined with Lokomat (Pre-test)
Outcome: Late Life Function and Disability Instrument | 0 | {"evidence_spans": [{"end": 23436, "start": 23289, "text": "ticipants (Figure 1B; Table 2). With the exception of the 6-minute walk test and LLFDI, p \u2265 0.16, all secondary measures revealed significant impr"}], "id": "160", "pmcid": "2708184", "prompt_id": "160", "split_group_id": "2708184", "votes": {"0": 1}} |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (all doses) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: Decreases in diastolic blood pressure | 0 | {"evidence_spans": [{"end": 22372, "start": 22232, "text": " different from placebo or rosiglitazone (0.9\u20132.3 mmHg). Reductions in diastolic blood pressure also occurred with all treatments (0.7\u20131.4 m"}, {"end": 22373, "start": 22232, "text": " different from placebo or rosiglitazone (0.9\u20132.3 mmHg). Redu... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (all doses) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: Pulse variations | 1 | {"evidence_spans": [{"end": 22642, "start": 22554, "text": "azone, while pulse decreased by 1 beat/min with placebo. Changes in pulse for all doses "}, {"end": 22738, "start": 22554, "text": "azone, while pulse decreased by 1 beat/min with placebo. Changes in pulse for all doses of liraglutide were significant vs. plac... |
TITLE: Pilot study of Lokomat versus manual-assisted treadmill training for locomotor recovery post-stroke
ABSTRACT.BACKGROUND:
While manually-assisted body-weight supported treadmill training (BWSTT) has revealed improved locomotor function in persons with post-stroke hemiparesis, outcomes are inconsistent and i... | Intervention: Body-weight supported treadmill training combined with Lokomat
Comparator: Manually-assisted body-weight supported treadmill training
Outcome: Self-selected overground walk velocity | 0 | {"evidence_spans": [{"end": 1330, "start": 1211, "text": "ESULTS:\r\nNo significant differences in primary outcomes were revealed between Lokomat and manual groups as a result of "}], "id": "155", "pmcid": "2708184", "prompt_id": "155", "split_group_id": "2708184", "votes": {"0": 1}} |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: Fasting plasma glucose at week 26 | -1 | {"evidence_spans": [{"end": 1468, "start": 1144, "text": "e 8.4%). Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) ... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.2 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: Reductions in systolic blood pressure | 0 | {"evidence_spans": [{"end": 22231, "start": 22039, "text": "ied forward. \r\n\r\nBODY.RESULTS.BLOOD PRESSURE AND PULSE:\r\nAlthough decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6\u20132.8 mmHg), they were not significantl"}, {"end": 22232, "start": 22039, "text": "ied forward. ... |
TITLE: Trends in Use of Referral Hospital Services for Care of Sick Newborns in a Community-based Intervention in Tangail District, Bangladesh
ABSTRACT:
The Projahnmo-II Project in Mirzapur upazila (sub-district), Tangail district, Bangladesh, is promoting care-seeking for sick newborns through health education o... | Intervention: Promotion by CHWs of maternal and newborn-care interventions
Comparator: Comparison arm
Outcome: Care-seeking from the Kumudini Hospital for ill newborns | 1 | {"evidence_spans": [{"end": 1008, "start": 732, "text": "5. Increases were observed in self-referral of sick newborns for care, compliance after referral by the CHWs, and care-seeking from qualified providers and from the Kumudini Hospital, and decreases were observed in care-seeking from unqualified providers in the i... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% | 1 | {"evidence_spans": [{"end": 16110, "start": 15956, "text": "raglutide was dose dependent (Fig. 4). At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and \u2264 6.5%, respectivel"}, {"end": 16457, "start": 16119, "text": "ed with 8% and 4% for placebo (Fig. 4). The estimated pro... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.2 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: HOMA-B | 1 | {"evidence_spans": [{"end": 20902, "start": 20728, "text": " either rosiglitazone or placebo (Table 2; P \u2264 0.02). HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only d"}, {"end": 20941, "start": 20728, "text": " either rosiglitazone or placebo (Tab... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Liraglutide (1.2 mg) plus glimepiride
Outcome: Patients reaching HbA1c goals less than 7.0% | 1 | {"evidence_spans": [{"end": 16449, "start": 15956, "text": "raglutide was dose dependent (Fig. 4). At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and \u2264 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with ei... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (0.6 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: HbA1c level at 26 weeks | 0 | {"evidence_spans": [{"end": 14367, "start": 14167, "text": "); rosiglitazone: \u22120.7% (\u22120.9, \u22120.4). All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001). Liraglutide 0.6 m"}, {"end": 14367, "start": 14169, "text": " ... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: ADA postprandial plasma glucose goals less than 10.0 mmol/l | 1 | {"evidence_spans": [{"end": 19623, "start": 19433, "text": "SULTS.EFFICACY.PPG MEASUREMENTS < 10.0 MMOL/L:\r\nThe percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compar"}], "id": "128", "pmcid": "2871176", "prompt_id": "128", "split_gro... |
TITLE: Is the operative delivery rate in low-risk women dependent on the level of birth care? A randomised controlled trial
ABSTRACT.OBJECTIVE:
To investigate possible differences in operative delivery rate among low-risk women, randomised to an alongside midwifery-led unit or to standard obstetric units within t... | Intervention: Special unit
Comparator: Normal unit & Special unit
Outcome: Perineal outcome: the number of episiotomies or the incidence of sphincter injuries | 0 | {"evidence_spans": [{"end": 19672, "start": 19524, "text": ".RESULTS.MODE OF DELIVERY.PERINEAL OUTCOME:\r\nThere was no significant difference between the three groups concerning the number of episiotomies or t"}, {"end": 19904, "start": 19524, "text": ".RESULTS.MODE OF DELIVERY.PERINEAL OUTCOME:\r\nThere was no signif... |
TITLE: Pilot study of Lokomat versus manual-assisted treadmill training for locomotor recovery post-stroke
ABSTRACT.BACKGROUND:
While manually-assisted body-weight supported treadmill training (BWSTT) has revealed improved locomotor function in persons with post-stroke hemiparesis, outcomes are inconsistent and i... | Intervention: Body-weight supported treadmill training combined with Lokomat (Post-test)
Comparator: Body-weight supported treadmill training combined with Lokomat (Pre-test)
Outcome: 6-minute walk test | 0 | {"evidence_spans": [{"end": 23436, "start": 23289, "text": "ticipants (Figure 1B; Table 2). With the exception of the 6-minute walk test and LLFDI, p \u2265 0.16, all secondary measures revealed significant impr"}], "id": "159", "pmcid": "2708184", "prompt_id": "159", "split_group_id": "2708184", "votes": {"0": 1}} |
TITLE: Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial
ABSTRACT.BACKGROUND:
Endometriosis is associated with an inflammatory response. Hence infliximab, an anti-TNF-α monoclonal antibody, might relieve pain.
ABSTRACT.METHODS:
A randomized placebo-controlled t... | Intervention: Infliximab
Comparator: Placebo
Outcome: Tissue examination by routine pathology | 0 | {"evidence_spans": [{"end": 21027, "start": 20742, "text": ") and 8.2 (3\u201315) mm, respectively. During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates. Routine patholo... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: Proinsulin : insulin ratio | -1 | {"evidence_spans": [{"end": 20726, "start": 20566, "text": "F PANCREATIC B-CELL FUNCTION AND INSULIN RESISTANCE:\r\nReductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared wi"}, {"end": 20728, "start": 20566, "text": "F PANCREATIC B-CELL FUNCTION AND INSULIN RESISTANCE:\r... |
TITLE: Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial
ABSTRACT.BACKGROUND:
Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its ... | Intervention: Dihydroartemisinin-piperaquine
Comparator: Chloroquine
Outcome: Cure rate at day 28 | 0 | {"evidence_spans": [{"end": 23762, "start": 23720, "text": "compared to the chloroquine arm (145/266 ("}], "id": "177", "pmcid": "2864284", "prompt_id": "177", "split_group_id": "2864284", "votes": {"0": 1}} |
TITLE: Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial
ABSTRACT.BACKGROUND:
Endometriosis is associated with an inflammatory response. Hence infliximab, an anti-TNF-α monoclonal antibody, might relieve pain.
ABSTRACT.METHODS:
A randomized placebo-controlled t... | Intervention: Infliximab
Comparator: Placebo
Outcome: Macroscopic aspect of the tissue | 0 | {"evidence_spans": [{"end": 20897, "start": 20742, "text": ") and 8.2 (3\u201315) mm, respectively. During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometrio"}, {"end": 20945, "start": 20742, "text": ") and 8.2 (3\u201315) mm, respectively. During surgery,... |
TITLE: Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial
ABSTRACT.BACKGROUND:
Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its ... | Intervention: Dihydroartemisinin-piperaquine
Comparator: Chloroquine
Outcome: Fever resolution by day 2 | 0 | {"evidence_spans": [{"end": 23559, "start": 23386, "text": "mpared to 45/268 (16.8%) in the chloroquine group (p = 0.049). By day 2 there was no longer a significant difference in the proportion with fever (3/265 (1.1%) for dihydroar"}], "id": "175", "pmcid": "2864284", "prompt_id": "175", "split_group_id": "2864284", ... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: Fasting plasma glucose at week 26 | -1 | {"evidence_spans": [{"end": 1396, "start": 1144, "text": "e 8.4%). Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9."}, {"end"... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.2 mg) plus glimepiride
Comparator: Placebo plus glimepiride
Outcome: ADA postprandial plasma glucose goals less than 10.0 mmol/l | 1 | {"evidence_spans": [{"end": 19623, "start": 19433, "text": "SULTS.EFFICACY.PPG MEASUREMENTS < 10.0 MMOL/L:\r\nThe percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compar"}, {"end": 19624, "start": 19433, "text": "SULTS.EFFICACY.PPG MEASU... |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.2 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: Proinsulin : insulin ratio | -1 | {"evidence_spans": [{"end": 20726, "start": 20566, "text": "F PANCREATIC B-CELL FUNCTION AND INSULIN RESISTANCE:\r\nReductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared wi"}, {"end": 20728, "start": 20566, "text": "F PANCREATIC B-CELL FUNCTION AND INSULIN RESISTANCE:\r... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.